PAPADOPOULOS STELIOS 4

What Happened
Stelios Papadopoulos, a director of Ovid Therapeutics, was granted 17,578 restricted stock units (RSUs) on April 7, 2026. The award is valued at $45,000 based on a grant price of $2.56 per share. The RSUs were issued in lieu of his annual cash retainer for board service.

Key Details

• Transaction type: Award/Grant (code A) on 2026-04-07; Form 4 filed 2026-04-09 (appears timely).
• Amount: 17,578 RSUs at $2.56 per share, total value $45,000.
• Vesting: 25% vested upon grant (approximately 4,395 RSUs) and the remaining 75% vest 25% on each of June 30, 2026, Sept 30, 2026, and Dec 31, 2026, subject to continuous service (per footnote F1).
• Shares owned after transaction: Not specified in this filing.
• Other notes: Award issued under the company’s Non-Employee Director Compensation Policy in lieu of cash. No tax withholding, sale, or 10b5-1 plan mentioned.

Context
Director RSU grants are a common form of board compensation and do not necessarily indicate the director’s view on the company’s stock. Unlike open-market purchases or insider sales, awards primarily reflect routine compensation practices rather than a direct market signal.